000130669 001__ 130669
000130669 005__ 20240228143452.0
000130669 0247_ $$2doi$$a10.1093/neuonc/nov322
000130669 0247_ $$2pmid$$apmid:26826203
000130669 0247_ $$2pmc$$apmc:PMC4864264
000130669 0247_ $$2ISSN$$a1522-8517
000130669 0247_ $$2ISSN$$a1523-5866
000130669 0247_ $$2altmetric$$aaltmetric:5063745
000130669 037__ $$aDKFZ-2017-05747
000130669 041__ $$aeng
000130669 082__ $$a610
000130669 1001_ $$aThomas, Christian$$b0
000130669 245__ $$aMethylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups.
000130669 260__ $$aOxford$$bOxford Univ. Press$$c2016
000130669 3367_ $$2DRIVER$$aarticle
000130669 3367_ $$2DataCite$$aOutput Types/Journal article
000130669 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522147754_11125
000130669 3367_ $$2BibTeX$$aARTICLE
000130669 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130669 3367_ $$00$$2EndNote$$aJournal Article
000130669 520__ $$aChoroid plexus tumors are intraventricular neoplasms derived from the choroid plexus epithelium. A better knowledge of molecular factors involved in choroid plexus tumor biology may aid in identifying patients at risk for recurrence.Methylation profiles were examined in 29 choroid plexus papillomas (CPPs, WHO grade I), 32 atypical choroid plexus papillomas (aCPPs, WHO grade II), and 31 choroid plexus carcinomas (CPCs, WHO grade III) by Illumina Infinium HumanMethylation450 Bead Chip Array.Unsupervised hierarchical clustering identified 3 subgroups: methylation cluster 1 (pediatric CPP and aCPP of mainly supratentorial location), methylation cluster 2 (adult CPP and aCPP of mainly infratentorial location), and methylation cluster 3 (pediatric CPP, aCPP, and CPC of supratentorial location). In methylation cluster 3, progression-free survival (PFS) accounted for a mean of 72 months (CI, 55-89 mo), whereas only 1 of 42 tumors of methylation clusters 1 and 2 progressed (P< .001). On stratification of outcome data according to WHO grade, all CPCs clustered within cluster 3 and were associated with shorter overall survival (mean, 105 mo [CI, 81-128 mo]) and PFS (mean, 55 mo [CI, 36-73 mo]). The aCPP of methylation cluster 3 also progressed frequently (mean, 69 mo [CI, 44-93 mo]), whereas no tumor progression was observed in aCPP of methylation clusters 1 and 2 (P< .05). Only 1 of 29 CPPs recurred.Methylation profiling of choroid plexus tumors reveals 3 distinct subgroups (ie, pediatric low-risk choroid plexus tumors [cluster 1], adult low-risk choroid plexus tumors [cluster 2], and pediatric high-risk choroid plexus tumors [cluster 3]) and may provide useful prognostic information in addition to histopathology.
000130669 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000130669 588__ $$aDataset connected to CrossRef, PubMed,
000130669 7001_ $$0P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aSill, Martin$$b1$$udkfz
000130669 7001_ $$aRuland, Vincent$$b2
000130669 7001_ $$aWitten, Anika$$b3
000130669 7001_ $$aHartung, Stefan$$b4
000130669 7001_ $$aKordes, Uwe$$b5
000130669 7001_ $$aJeibmann, Astrid$$b6
000130669 7001_ $$aBeschorner, Rudi$$b7
000130669 7001_ $$aKeyvani, Kathy$$b8
000130669 7001_ $$aBergmann, Markus$$b9
000130669 7001_ $$0P:(DE-He78)3494efbbc54460b109fe9eab0595adda$$aMittelbronn, Michel$$b10$$udkfz
000130669 7001_ $$aPietsch, Torsten$$b11
000130669 7001_ $$aFelsberg, Jörg$$b12
000130669 7001_ $$aMonoranu, Camelia M$$b13
000130669 7001_ $$aVarlet, Pascale$$b14
000130669 7001_ $$aHauser, Peter$$b15
000130669 7001_ $$aOlar, Adriana$$b16
000130669 7001_ $$aGrundy, Richard G$$b17
000130669 7001_ $$aWolff, Johannes E$$b18
000130669 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b19$$udkfz
000130669 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b20$$udkfz
000130669 7001_ $$0P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aBewerunge-Hudler, Melanie$$b21$$udkfz
000130669 7001_ $$0P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aHovestadt, Volker$$b22$$udkfz
000130669 7001_ $$avon Deimling, Andreas$$b23
000130669 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b24$$udkfz
000130669 7001_ $$aPaulus, Werner$$b25
000130669 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b26$$udkfz
000130669 7001_ $$aHasselblatt, Martin$$b27
000130669 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nov322$$gVol. 18, no. 6, p. 790 - 796$$n6$$p790 - 796$$tNeuro-Oncology$$v18$$x1523-5866$$y2016
000130669 909CO $$ooai:inrepo02.dkfz.de:130669$$pVDB
000130669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3494efbbc54460b109fe9eab0595adda$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000130669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000130669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000130669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000130669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000130669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000130669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000130669 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000130669 9141_ $$y2016
000130669 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000130669 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000130669 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000130669 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130669 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130669 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130669 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130669 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130669 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130669 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130669 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000130669 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000130669 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x1
000130669 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x2
000130669 9201_ $$0I:(DE-He78)W110-20160331$$kW110$$lMicroarray Unit$$x3
000130669 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lMolekulare Genetik$$x4
000130669 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x5
000130669 9201_ $$0I:(DE-He78)L501-20160331$$kL501$$lDKTK Frankfurt$$x6
000130669 980__ $$ajournal
000130669 980__ $$aVDB
000130669 980__ $$aI:(DE-He78)C060-20160331
000130669 980__ $$aI:(DE-He78)G380-20160331
000130669 980__ $$aI:(DE-He78)B062-20160331
000130669 980__ $$aI:(DE-He78)W110-20160331
000130669 980__ $$aI:(DE-He78)B060-20160331
000130669 980__ $$aI:(DE-He78)L101-20160331
000130669 980__ $$aI:(DE-He78)L501-20160331
000130669 980__ $$aUNRESTRICTED